Triomics Raises $22M in Series B
Triomics raises $22M Series B led by Battery Ventures to scale its AI platform for automating clinical trial matching and data entry at cancer centers.
Triomics Raises $22M in Series B
Triomics, a San Francisco, CA-based healthcare AI startup focused on oncology workflows, has raised $22 million in Series B funding.
Investors
The round was led by Battery Ventures, with participation from existing investors including Nexus Venture Partners, Lightspeed, Y Combinator, and others.
Triomics Use of Funds
The company intends to use the capital to further develop its oncology-specific AI models and expand its reach to more medical institutions to address clinical staff burnout and administrative complexity.
About Triomics
Founded in 2021 by Sarim Khan and Hrituraj Singh, Triomics develops oncology-specific AI tools designed to reduce administrative burden for clinicians and hospital staff. Its platform automates labor-intensive tasks such as clinical trial matching, patient chart summarization, appointment preparation, and tumor registry submissions. Triomics works with leading healthcare institutions such as Memorial Sloan Kettering Cancer Center and Yale Cancer Center.
Funding Details
Company: Triomics, Inc.
Raised: $22M
Round: Series B
Funding Date: May 27, 2026
Lead Investor: Battery Ventures
Additional Investors: Nexus Venture Partners, Lightspeed, Y Combinator
Company Website: https://triomics.com/
Software Category: Healthcare AI / HealthTech
Source: https://techcrunch.com/2026/05/27/triomics-nabs-22m-to-bring-oncology-specific-ai-to-cancer-centers/
